Antineoplastic Agents, Hormonal - Adverse effects
Research News and Information

Monday, November 23, 2009

[Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer]

30 Aug 2009 Recently, some new anticancer agents and hormonal agents can be used to treat breast cancer, and more patients are administering combinations of these drugs in clinical practice. Tegafur and Uracil (UFT) have been widely used for the postoperative ... Read more...

[Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors]

30 Aug 2009 BACKGROUND: Recently, aromatase inhibitors (AI) are widely used in postoperative adjuvant therapy for breast cancer. Nevertheless, studies of postoperative therapeutic strategies for recurrent breast cancer are insufficient. SUBJECTS AND METHOD: ... Read more...

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

22 Aug 2009 PURPOSE: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metastatic NETs is a matter of ... Read more...

Latest indexed articles for 'Antineoplastic Agents, Hormonal - Adverse effects'

These are the very latest articles for this heading:

• [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer] 30 Aug 2009
• [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors] 30 Aug 2009
• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. 22 Aug 2009
• Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. 18 Aug 2009
• Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. 13 Aug 2009
• Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer. Aug 2009
• Risk of depressive events in long-term surviving patients affected by hormone-related cancer according to time after diagnosis. Aug 2009
• [Biochemical markers of bone turnover. New aspect. Bone metabolic markers in prostatic carcinoma] 30 Jul 2009
• Sexual health issues in Sudanese women before and during hormonal treatment for breast cancer. 30 Jul 2009
• Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. 30 Jul 2009
• Tamoxifen-induced ultraviolet, recall dermatitis. 30 Jul 2009
• An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. 30 Jul 2009
• Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study. 26 Jul 2009
• [And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)] 21 Jul 2009
• Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. 11 Jul 2009
• Pharmacogenomics of tamoxifen therapy. 30 Jun 2009
• Women's health, breast health: a review of the gynecologic effects of breast cancer. 29 Jun 2009
• Cytodiagnostic problems in cervicovaginal smears from symptomatic breast cancer patients on tamoxifen therapy. 29 Jun 2009
• A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. 20 Jun 2009
• Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy. 18 Jun 2009

See a longer list of these articles.

Technical information about 'Antineoplastic Agents, Hormonal'

Definition: Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Registry Number: 0

Descriptor UI: D018931

Alternative terms: Antineoplastic Agents, Hormonal; Hormonal Agents, Antineoplastic; Hormonal Antineoplastic Agents; Hormonal Antineoplastics; Antineoplastic Hormonal Drugs; Drugs, Antineoplastic Hormonal; Hormonal Drugs, Antineoplastic; Hormonal Antineoplastic Drugs; Antineoplastics, Hormonal; Antineoplastic Hormonal Agents; Agents, Antineoplastic Hormonal; Antineoplastic Drugs, Hormonal;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.248.169;

History Note: 96

Technical Notes: consider also NEOPLASMS, HORMONE-DEPENDENT /drug ther